|Day Low/High||49.76 / 50.06|
|52 Wk Low/High||37.62 / 55.00|
Animal health and oncology deal activity is heating up in 2017.
After a court halts Regeneron's sales of Praluent, Jim Cramer sees opportunity in Amgen.
A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.
Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.
As we all know, the stock market and the economy abhor uncertainty.
It was a volatile end to the week after federal investigators reopened a case into Hillary Clinton's email server.
The Chart of the Day demonstrates the widening schism between the real economy and stock prices. The issuance of negative-yielding European corporate debt by Henkel, Deutsche Bahn and Sanofi are the definition of insanity. Euro bond prices are in t...
Regular readers of my diary know that I sometimes post something that replicates the theme of the Tell Me Something I Don't Know segment on MSNBC's Hardball With Chris Matthews. So ... "Tell me something I don't know, Dougie." OK, here goes: Henkel ...
Mylan's EpiPen continues to dominate the market as a one-time rival looks to come back.
Clinton goes after the drug companies again -- for starters.
Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.
The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...
Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.
Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...
The sector seems to be rebounding after tumbling by more than 40%.
The mobile-gaming market is expected to surpass console games this year, according to Deloitte.
Our first upside target is the $50 to $52 area and a close below $40 would extend the base.
Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.
U.K. banks continue to get crushed in the wake of last week's Brexit vote as gold, a typical safe-haven investment, surged ahead.
Biotech company BioMarin Pharmacuetical's shares are moving sharply higher on heavy volume in Friday's session.
The uptick in the small- and mid-cap space bodes well for future capital appreciation.
It is hard to see much growth in the market overall, until earnings growth returns.
The M&A activity is an incredible and a welcome sign.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.
The market is off to a good start, as the futures had portended earlier. Industrial and construction stocks seem to be doing particularly well. Rail-car maker Greenbrier Cos. (GBX) continues to show strength even after a recent earnings report that ...
Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
Shareholders should have been running from the drugmaker long before Tuesday's news that partner Sanofi was leaving first.
The ECB's monetary stimulus is working, and more may be on the way.